Skip to main content

Advertisement

SpringerLink
Log in

Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL)

Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias

  • Leitthema
  • Published:
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz Aims and scope

Zusammenfassung

Im Jahr 1997 wurde durch den Zusammenschluss der führenden Leukämie-Studiengruppen in Deutschland das Kompetenznetz Akute und Chronische Leukämien (KNL) gegründet. Wichtige Resultate sind neue Kooperationsstudien und Forschungsprojekte, die Fortführung und Erweiterung bestehender und die Gründung neuer nationaler Studiengruppen, die Verbesserung der Studieninfrastruktur sowie die Einrichtung von Patientenregistern und Biomaterialbanken. 2003 führte das Konzept des KNL zur Gründung des European LeukemiaNet (ELN). In der Folge wurden in internationaler Kooperation zahlreiche europäische Managementleitlinien erarbeitet und mehrere länderübergreifende Projekte und Studien durchgeführt. Ziel des Netzes ist die Heilung der Leukämien durch kooperative Forschung.

Abstract

The Competence Network “Acute and Chronic Leukemias” was founded in 1997 by the consolidation of the leading leukemia study groups in Germany. Key results are the development of new trials and cooperative studies, the setup of patient registries and biobanking facilities, as well as the improvement of study infrastructure. In 2003, the concept of the competence network contributed to the foundation of the European LeukemiaNet (ELN). Synergy with the ELN resulted in cooperation on a European and international level, standardization of diagnostics and treatment, and recommendations for each leukemia and interdisciplinary specialty. The ultimate goal of the network is the cure of leukemia through cooperative research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Hehlmann R, Berger U, Aul C et al (2004) Das Kompetenznetzwerk akute und chronische Leukämien. Dtsch Med Wochenschr 129:2660–2665

    Article  CAS  PubMed  Google Scholar 

  2. Hehlmann R, Berger U, Aul C et al (2004) The German competence network ’Acute and chronic leukemias‘. Leukemia 18:665–669

    Article  CAS  PubMed  Google Scholar 

  3. Büchner T, Schlenk RF, Schaich M et al (2012) Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol 30:3604–3610

    Article  PubMed  CAS  Google Scholar 

  4. Hoelzer D, Bassan R, Dombret H et al (in press) Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology

  5. Gökbuget N (2013) How I treat older patients with ALL. Blood 122:1366–1375

    Article  PubMed  CAS  Google Scholar 

  6. Döhner H, Weisdorf DJ, Bloomfield CD (2015) Acute Myeloid leukemia. N Engl J Med 373:1136–1152

    Article  PubMed  CAS  Google Scholar 

  7. Döhner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474

    Article  PubMed  CAS  Google Scholar 

  8. Sanz MA, Grimwade D, Tallman MS et al (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875–1891

    Article  CAS  PubMed  Google Scholar 

  9. Cornelissen JJ, Gratwohl A, Schlenk RF et al (2012) The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 9:579–590

    Article  CAS  PubMed  Google Scholar 

  10. Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pospisilova S, Gonzalez D, Malcikova J et al (2012) ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26:1458–1461

    Article  CAS  PubMed  Google Scholar 

  12. Rawstron AC, Böttcher S, Letestu R et al (2013) Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 27:142–149

    Article  CAS  PubMed  Google Scholar 

  13. Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Baccarani M, Cortes J, Pane F et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041–6051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hehlmann R, Hochhaus A, Baccarani M et al (2007) Chronic myeloid leukaemia. Lancet 370:342–350

    Article  CAS  PubMed  Google Scholar 

  16. Hehlmann R (2012) How I treat CML blast crisis. Blood 120:737–747

    Article  CAS  PubMed  Google Scholar 

  17. Guilhot J, Baccarani M, Clark RE et al (2012) Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 119:5963–5971

    Article  CAS  PubMed  Google Scholar 

  18. Pfirrmann M, Hochhaus A, Lauseker M et al (2011) Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 25:1433–1438

    Article  CAS  PubMed  Google Scholar 

  19. White HE, Hedges J, Bendit I et al (2013) Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem 59:938–948

    Article  CAS  PubMed  Google Scholar 

  20. Cross NC, White HE, Müller MC et al (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172–2175

    Article  CAS  PubMed  Google Scholar 

  21. White HE, Matejtschuk P, Rigsby P et al (2010) Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 116:111–117

    Article  CAS  Google Scholar 

  22. Müller MC, Cross NC, Erben P et al (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:1957–1963

    Article  PubMed  CAS  Google Scholar 

  23. Branford S, Cross NC, Hochhaus A et al (2006) Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20:1925–1930

    Article  CAS  PubMed  Google Scholar 

  24. Hughes T, Deininger M, Hochhaus A et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28–37

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Cross NC, White HE, Colomer D et al (2015) Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29:999–1003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Soverini S, Hochhaus A, Nicolini FE et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118:1208–1215

    Article  CAS  PubMed  Google Scholar 

  27. Malcovati L, Hellström-Lindberg E, Bowen D et al (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:2943–2964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Barbui T, Barosi G, Birgegard G et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770

    Article  PubMed  PubMed Central  Google Scholar 

  29. Barosi G, Birgegard G, Finazzi G et al (2009) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148:961–963

    Article  PubMed  Google Scholar 

  30. Barosi G, Birgegard G, Finazzi G et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113:4829–4833

    Article  CAS  PubMed  Google Scholar 

  31. Jovanovic JV, Ivey A, Vannucchi AM et al (2013) Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 27:2032–2039

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Østergaard M, Nyvold CG, Jovanovic JV et al (2011) Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. Leukemia 25:1168–1173

    Article  PubMed  Google Scholar 

  33. Béné MC, Nebe T, Bettelheim P et al (2011) Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 25:567–574

    Article  PubMed  Google Scholar 

  34. Haferlach T, Kohlmann A, Wieczorek L et al (2010) Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 28:2529–2537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Mills KI, Kohlmann A, Williams PM et al (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood 114:1063–1072

    Article  CAS  PubMed  Google Scholar 

  36. Kohlmann A, Bullinger L, Thiede C et al (2010) Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 24:1216–1220

    Article  CAS  PubMed  Google Scholar 

  37. Kohlmann A, Kipps TJ, Rassenti LZ et al (2008) An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in Leukemia study prephase. Br J Haematol 142:802–807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Staal FJ, Cario G, Cazzaniga G et al (2006) Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia 20:1385–1392

    Article  CAS  PubMed  Google Scholar 

  39. Haferlach C, Rieder H, Lillington DM et al (2007) Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 46:494–499

    Article  CAS  PubMed  Google Scholar 

  40. Cilloni D, Renneville A, Hermitte F et al (2009) Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 27:5195–5201

    Article  CAS  PubMed  Google Scholar 

  41. Consensus morphology collection. www.leukemia-net.org

  42. Kröger NM, Deeg JH, Olavarria E et al (2009) Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia 29:2126–2133

    Article  CAS  Google Scholar 

  43. Ruutu T, Gratwohl A, de Witte T et al (2014) Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 49:168–173

    Article  CAS  PubMed  Google Scholar 

  44. Ruutu T, van Biezen A, Hertenstein B et al (2012) Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47:1459–1464

    Article  CAS  PubMed  Google Scholar 

  45. Ruutu T, Barosi G, Benjamin RJ et al (2007) Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 92:95–100

    Article  PubMed  Google Scholar 

  46. Dreger P, Corradini P, Kimby E et al (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21:12–17

    Article  CAS  PubMed  Google Scholar 

  47. de Witte T, Brand R, van Biezen A et al (2006) The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica 91:750–756

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Fakultät Mannheim der Universität Heidelberg, Pettenkoferstr. 22, 68169, Mannheim, Deutschland

    Ute Kossak-Roth, Susanne Saußele, Andreas Reiter &  Rüdiger Hehlmann

  2. Klinik für Onkologie und Hämatologie, HELIOS St. Johannes Klinik, Duisburg, Deutschland

    Carlo Aul

  3. Medizinische Klinik A, Universitätsklinikum, Münster, Deutschland

    Thomas Büchner

  4. Klinik für Innere Medizin III, Universitätsklinikum, Ulm, Deutschland

    Hartmut Döhner

  5. Institut für Medizinische Informatik, Westfälische Wilhelms-Universität, Münster, Deutschland

    Martin Dugas

  6. Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Deutschland

    Gerhard Ehninger & Christoph Röllig

  7. Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule, Hannover, Deutschland

    Arnold Ganser & Michael Heuser

  8. Klinik für Onkologie, Hämatologie und Palliativmedizin, Marien Hospital, Düsseldorf, Deutschland

    Aristoteles Giagounidis

  9. Onkologikum Frankfurt am Museumsufer, Frankfurt, Deutschland

    Nicola Gökbuget & Dieter Hoelzer

  10. Klinik für Hämatologie, Onkologie und Palliativmedizin, Johannes Wesling Klinikum, Minden, Deutschland

    Martin Griesshammer

  11. Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München, Deutschland

    Jörg Hasford

  12. Medizinische Klinik und Poliklinik III, Campus Großhadern, Klinikum der Universität, München, Deutschland

    Wolfgang Hiddemann

  13. Klinik für Innere Medizin II, Universitätsklinikum, Jena, Deutschland

    Andreas Hochhaus

  14. Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum, Leipzig, Deutschland

    Dietger Niederwieser

Authors
  1. Ute Kossak-Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Saußele
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlo Aul
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Büchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hartmut Döhner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin Dugas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gerhard Ehninger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Arnold Ganser
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Aristoteles Giagounidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nicola Gökbuget
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Martin Griesshammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jörg Hasford
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Michael Heuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Wolfgang Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Andreas Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Dieter Hoelzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Dietger Niederwieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Andreas Reiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Christoph Röllig
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Rüdiger Hehlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rüdiger Hehlmann.

Ethics declarations

Interessenkonflikt

U. Kossak-Roth, S. Saußele, C. Aul, T. Büchner, H. Döhner, M. Dugas, G. Ehninger, A. Ganser, A. Giagounidis, N. Gökbuget, M. Griesshammer, J. Hasford, M. Heuser, W. Hiddemann, A. Hochhaus, D. Hoelzer, D. Niederwieser, A. Reiter, C. Röllig und R. Hehlmann geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kossak-Roth, U., Saußele, S., Aul, C. et al. Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL). Bundesgesundheitsbl. 59, 444–453 (2016). https://doi.org/10.1007/s00103-016-2315-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00103-016-2315-x

Schlüsselwörter

Keywords

Search

Navigation